CRDF vs. KOD, IPSC, OPT, IPHA, ABOS, ELEV, PSTX, CMPX, XFOR, and GRPH
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Kodiak Sciences (KOD), Century Therapeutics (IPSC), Opthea (OPT), Innate Pharma (IPHA), Acumen Pharmaceuticals (ABOS), Elevation Oncology (ELEV), Poseida Therapeutics (PSTX), Compass Therapeutics (CMPX), X4 Pharmaceuticals (XFOR), and Graphite Bio (GRPH). These companies are all part of the "biological products, except diagnostic" industry.
Cardiff Oncology (NASDAQ:CRDF) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.
Cardiff Oncology has higher revenue and earnings than Kodiak Sciences. Cardiff Oncology is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Kodiak Sciences has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,492.01%. Cardiff Oncology's return on equity of -50.13% beat Kodiak Sciences' return on equity.
Cardiff Oncology has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.
Cardiff Oncology presently has a consensus price target of $10.50, indicating a potential upside of 151.20%. Kodiak Sciences has a consensus price target of $5.50, indicating a potential upside of 62.72%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Cardiff Oncology is more favorable than Kodiak Sciences.
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 6.3% of Cardiff Oncology shares are owned by insiders. Comparatively, 45.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Kodiak Sciences had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 1 mentions for Kodiak Sciences and 0 mentions for Cardiff Oncology. Kodiak Sciences' average media sentiment score of 0.11 beat Cardiff Oncology's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the news media.
Cardiff Oncology received 19 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 61.67% of users gave Cardiff Oncology an outperform vote while only 28.13% of users gave Kodiak Sciences an outperform vote.
Summary
Cardiff Oncology beats Kodiak Sciences on 10 of the 17 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
